IQVIA

The fifth product scoped platform vendor here. IQVIA's durable assets are its health data holdings, clinical research services, and domain expertise; IQVIA.ai is an agentic layer over those assets launched in March 2026. The company's own framing, that the platform combines its data and expertise with NVIDIA infrastructure, correctly identifies the data as the foundation. A pharmaceutical company does not select IQVIA for its agents.

The infrastructure stack is named with unusual specificity for a company this size: NVIDIA Nemotron, NeMo Agent Toolkit, NeMo Customizer for fine tuning, NeMo Guardrails for deployment safety, Dynamo, and LangChain. Naming the guardrail layer explicitly is worth noting. Held back from A because Healthcare grade AI is a trademarked positioning term rather than a described methodology, and no model cards, benchmarks, or validation results were retrieved to substantiate what distinguishes it beyond data quality and domain tuning.

Adoption breadth is exceptional and specific: more than 150 intelligent agents deployed across internal teams and client environments, and 19 of the top 20 pharmaceutical companies reported to have begun incorporating IQVIA agents into workflows. More than 100 AI related patents filed. Held back from A because begun incorporating is a low bar that spans pilot through production, no outcome figures were retrieved for any agent, and the platform launched in March 2026, so deployment depth is unproven relative to breadth.

The company states it uses a range of privacy enhancing technologies and safeguards to protect individual privacy while analyzing health data at scale, and cites NeMo Guardrails in the agent deployment stack, which is a named technical control rather than a general assurance. Held back from A because no specific de identification standard, consent framework, or independent privacy audit was retrieved, and the scale of the underlying data holdings makes that disclosure more consequential here than for most vendors in this index.

No public pricing. Contact the vendor. Enterprise agreements with life sciences organizations, typically bundled with existing data and services relationships. Third party analysis notes the platform is structured as a multi year commitment rather than a discrete product, which increases switching costs once agents are embedded in clinical and commercial processes; that lock in dynamic is worth weighing against a specialist alternative.

Coverage spans clinical, commercial, and real world evidence operations across the asset lifecycle, with named use cases including target identification, clinical data review, literature review, market assessment, and healthcare professional engagement. Held back from A because that range is very broad and mixes research functions with commercial targeting; a buyer should scope which agents are production ready for their specific function rather than assuming uniform maturity.